Summary
32 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
What to watch
- Revenue fell by 24% a year over the last 3 years.
- Out of every 100 USD of revenue, only 0.4 USD is left as net profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 102.0 USD for 1 USD of yearly profit. Over the last five years it was 8.5 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
Revenue grew by 0.8% a year over 5 years. Over the last 3 years it fell by 24% a year. Earnings per share fell by 26% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyWhere 100 USD of revenue goes
- Cost of sales 51 USD
- Sales and administration 62 USD
- Taxes and other -13 USD
- Net profit 0.4 USD
Net profit, industry median (Chemicals) 4.6 USD
Out of every 100 USD of revenue, 0.4 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash. The debt score is high even though free cash flow is negative.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.